Hansoh Pharmaceutical Group Company Limited (FRA:3KY)

Germany flag Germany · Delayed Price · Currency is EUR
3.940
-0.040 (-1.01%)
Last updated: Feb 20, 2026, 3:25 PM CET
Market Cap24.16B +87.5%
Revenue (ttm)1.57B +9.0%
Net Income568.30M +1.4%
EPS0.10 +5.9%
Shares Outn/a
PE Ratio42.51
Forward PE37.79
Dividend0.04 (1.02%)
Ex-Dividend DateSep 22, 2025
Volumen/a
Average Volume475
Open3.960
Previous Close3.980
Day's Range3.940 - 3.960
52-Week Range2.020 - 4.800
Betan/a
RSI40.82
Earnings DateMar 20, 2026

About FRA:3KY

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei... [Read more]

Industry Pharmaceutical Preparations
Founded 1995
Employees 9,313
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 3KY
Full Company Profile

Financial Performance

In 2024, FRA:3KY's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY Financial Statements